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Indications
Glecaprevir/pibrentasvir is Food and Drug Administration (FDA) approved for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for the treatment of patients with HCV genotype 1 infection who have been previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. 1 Indications for available pangenotypic, fixed-dose combination products are compared in Table 1 .
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Clinical Pharmacology
Glecaprevir is an HCV NS3/4A protease inhibitor. In assays, glecaprevir inhibited proteolytic activity of recombinant NS3/4A enzymes from clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. 1 Pibrentasvir is an HCV NS5A inhibitor that has demonstrated activity against laboratory and clinical isolates from subtypes 1a, 1b, 2a, 2b, 3a, 4a, 4b, 4d, 5a, 6a, 6e, and 6p. 1 In cell culture, resistance has been observed with some amino acid substitutions known to reduce antiviral susceptibility, and some combinations of amino acid substitutions were associated with greater reductions in susceptibility. In clinical trials, virologic failure was observed in small numbers of patients with HCV genotype 1, 2, or 3 infection; 2 treatment-naive patients with genotype 1 infection and 18 treatment-naive patients with HCV genotype 3 infection developed treatmentemergent amino acid substitutions in NS3 and/or NS5A. Treatment-emergent substitutions were also observed in several treatment-experienced patients who experienced virologic failure while receiving glecaprevir/pibrentasvir. Not all patients with virologic failure demonstrated treatment-emergent substitutions. 1 Baseline HCV polymorphisms in genotypes 1, 2, 4, 5, and 6 had no impact on treatment outcome; a lower response rate was observed in patients with genotype 3 HCV infection and baseline NS5A A30K polymorphism. 1 Pibrentasvir has been observed to retain some activity against some common resistance-conferring substitutions in HCV genotypes 1, 2, 3, 4, 5, or 6 that have been identified for other NS5A inhibitors, including those at key amino acid positions 28, 30, 31, or 93. Genotype 3a Y93H, which confers 200-fold or greater resistance to other NS5A inhibitors, conferred a 2.3-fold change in susceptibility to pibrentasvir. 4 
Pharmacokinetics
Following oral administration of the individual components of glecaprevir/pibrentasvir in healthy subjects, peak glecaprevir and pibrentasvir concentrations are both reached in 5 hours. Relative to fasting, administration with a moderate-to high-fat meal raises glecaprevir exposure by 83% to 163% and raises pibrentasvir exposure by 40% to 53%. Following administration of combination glecaprevir/pibrentasvir in noncirrhotic HCV-infected subjects, the peak concentration of glecaprevir was reduced by 51% relative to healthy subjects, but overall exposure was not altered. Peak concentration of pibrentasvir was reduced by 63% and overall exposure was 34% lower relative to healthy subjects. 1 Glecaprevir and pibrentasvir are both highly plasma protein bound (97.5% and greater than 99%, respectively). 1 The elimination half-life of glecaprevir is 6 hours, while that of pibrentasvir is 13 hours. Both are primarily eliminated via the biliary-fecal route, with greater than 90% of the dose excreted in the feces. Metabolism via cytochrome P450 (CYP-450) 3A is a secondary means of elimination for glecaprevir. Less than 1% of the dose of either component is excreted in the urine. 1 Glecaprevir has been shown to dosedependently increase pibrentasvir exposure, while pibrentasvir does not significantly alter glecaprevir exposure. 5 Glecaprevir and pibrentasvir area under the curve values were increased up to 56% in non-HCV-infected subjects with mild, moderate, severe, or end-stage renal impairment not on dialysis compared with subjects with normal renal function. Exposure to both agents was also similar with and without dialysis in dialysis-dependent non-HCV-infected subjects. In HCV-infected subjects with end-stage renal disease (with or without dialysis), glecaprevir exposure was 86% higher and pibrentasvir exposure was 54% higher than in subjects with normal renal function. No dose adjustment is necessary in patients with mild, moderate, or severe renal impairment, including those on dialysis. 1 In HCV-infected patients with mild hepatic impairment (Child-Pugh A) and compensated cirrhosis, glecaprevir exposure was increased approximately 2-fold while pibrentasvir exposure was similar to that of noncirrhotic HCV-infected subjects. In non-HCV-infected subjects with moderate hepatic impairment (Child-Pugh B), glecaprevir exposure was 100% higher than in subjects with normal hepatic function, while pibrentasvir exposure was 26% higher. In patients with severe hepatic impairment (Child-Pugh C), glecaprevir exposure was 11-fold higher than in subjects with normal hepatic function, while pibrentasvir exposure was 114% higher. No dose adjustment is necessary in patients with mild hepatic impairment. Use is not recommended Comments: In part 1 of the similar MAGELLAN-1 study, which enrolled 50 patients 18 to 70 years of age with HCV genotype 1 infection without cirrhosis but with prior virologic failure or relapse following HCV directacting antiviral therapy, SVR12 was achieved in 6 of 6 patients (100%; 95% CI, 61%-100%) treated with glecaprevir 200 mg/pibrentasvir 80 mg, in 21 of 22 (95%; 95% CI, 78%-99%) treated with glecaprevir 300 mg/pibrentasvir 120 mg plus ribavirin, and in 19 of 22 (86%; 95% CI, 67%-95%) treated with glecaprevir 300 mg/pibrentasvir 120 mg for 12 weeks. 10 The phase 2 SURVEYOR-I and SURVEYOR-II studies enrolled a total of 449 patients 18 to 70 years of age with HCV genotypes 1, 2, 3, 4, 5, or 6 without cirrhosis who were either treatment naive or had previously been treated with peginterferon-ribavirin. In these 2 dose-ranging studies using 8-and 12-week treatment periods, SVR12 was achieved in 92% to 100% of patients. 11 In a subsequent part 4 to the SURVEYOR-II study in patients treated with glecaprevir 300 mg/pibrentasvir 120 mg once daily for 8 weeks, sustained virologic response at posttreatment week 4 (SVR4) was achieved in 141 of 145 (97%) patients with genotype 2 infection, in 45 of 46 (98%) with genotype 4 infection, in 2 of 2 (100%) with genotype 5 infection, and in 10 of 10 (100%) with genotype 6 infection. 12 In a similar study (ENDURANCE-4) including 121 treatment-naive or treatment-experienced (interferon-or sofosbuvir-based regimen) patients with chronic HCV infection genotype 4, 5, or 6 treated with glecaprevir 300 mg/pibrentasvir 120 mg once daily for 12 weeks, SVR12 was achieved in 120 of 121 patients (99%; treatment failure occurred in one patient who discontinued treatment on day 12).
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Limitations: ENDURANCE-1 was a large study comparing 8-week and 12-week treatment durations in patients infected with HCV genotype 1, but numbers of patients with HIV coinfection or experience with sofosbuvir therapy were insufficient to draw any conclusions for those groups. Results have only been reported in a meeting abstract/presentation. As a postmarketing requirement, AbbVie will conduct an additional study evaluating the efficacy of glecaprevir/pibrentasvir in HCV genotype 1-infected patients previously treated with an NS5A inhibitor plus sofosbuvir. Study Design: Open-label, single-arm, multicenter, phase 3 study Study Funding: AbbVie Patients: 146 patients (18 years and older) with chronic HCV infection and with compensated cirrhosis. Patients were either treatment naive or had not responded to treatment with interferon or peginterferon with or without ribavirin, or to treatment with sofosbuvir plus ribavirin with or without peginterferon; all patients were NS3/4A and NS5A inhibitor-naive. Enrolled patients were infected with HCV genotype 1a (33%), 1b (27%), 2 (23%), 4 (11%), 5 (1%), or 6 (5%). Mean age was 60 years (range, 26 to 88 years); 62% of patients were male, and 82% were white. The majority (75%) were treatment naive. Intervention: Patients received glecaprevir 300 mg/ pibrentasvir 120 mg administered orally once daily for 12 weeks.
Results
Primary End Point(s)
• • SVR12 was achieved in 145 patients (99%; 95% CI, 98%-100%). In the subgroup of patients in whom previous regimens with telaprevir or boceprevir plus peginterferon-ribavirin, simeprevir plus sofosbuvir or peginterferon-ribavirin, or multiple protease inhibitors had failed, SVR12 was achieved at a rate of 100% (14 of 14 patients treated for 12 weeks and 13 of 13 patients treated for 16 weeks). In the subgroup in whom previous regimens with sofosbuvir/ledipasvir or daclatasvir plus peginterferon-ribavirin had failed, SVR12 was achieved in 14 of 16 patients (88%) treated for 12 weeks and in 17 of 18 (94%) treated for 16 weeks. In the subgroup of patients in whom previous regimens with ombitasvir/paritaprevir/ ritonavir with or without dasabuvir, daclatasvir plus asunaprevir, or other combinations had failed, SVR12 was achieved in 11 of 14 patients (79%) treated for 12 weeks and in 13 of 16 (81%) treated for 16 weeks.
Secondary End Point(s)
•
17
Limitations: The small number of patients in some genotype groups, the limited number of treatment-experienced patients, and the lack of an active control arm were all limitations of the EXPEDITION-1 study.
Reference: Gane EJ, et al, 2016 (EXPEDITION-4 trial) 18
Study Design: Open-label, multicenter study Study Funding: AbbVie Patients: 104 patients with renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m2) and HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. Patients were treatment naive or previously treated with an interferon-or sofosbuvir-based regimen. Most patients were male (76%) and white (62%); 42% were treatment experienced, 19% had compensated cirrhosis, and 82% were on dialysis. All genotypes were represented, although most patients had genotype 1 infection (genotype 1: 52%, genotype 2: 16%, genotype 3: 11%, genotype 4: 19%, genotype 5 and 6: 1% each). Intervention: Patients received glecaprevir 300 mg/ pibrentasvir 120 mg orally once daily for 12 weeks.
Results
Primary End Point(s):
• • SVR12 was achieved in 102 of 104 patients (98%) in the intention-to-treat analysis; 1 patient discontinued treatment early, and 1 patient was lost to follow-up. 
Secondary End Point(s)
Results
Primary End Point(s)
• • SVR12 was achieved in 98 of 99 patients (99%). 
Secondary End Point(s)
Results
Primary End Point(s)
• • SVR12 was achieved in 150 of 153 (98%) patients overall and in 150 of 151 (99%) patients included in the mITT analysis. One patient lost to follow-up at posttreatment week 12 returned at posttreatment week 24 and was found to have achieved sustained virologic response. 21 
Secondary End Point(s)
• • Virologic failure at week 8 occurred in one HCV genotype 3-infected patient with cirrhosis, who reported 85% adherence to the treatment regimen.
21
Comments: This study was conducted in Europe, Russia, and the United States. Limitations: Results have only been reported in a meeting abstract/presentation.
Contraindications, Warnings, and Precautions
Contraindications
Glecaprevir/pibrentasvir is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in patients receiving atazanavir or rifampin. 1 The contraindications, warnings, and precautions for glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are compared in Table 2. 1,2
Warnings and Precautions
Hepatitis B virus (HBV) reactivation has occurred in patients coinfected with HCV and HBV who were undergoing treatment with HCV direct-acting antivirals without HBV antiviral therapy. All patients should be tested for evidence of current or prior HBV infection before initiating treatment with glecaprevir/pibrentasvir. HCV/HBV coinfected patients should be monitored for hepatitis flare or HBV reactivation during HCV treatment and during posttreatment follow-up. HBV treatment should be initiated as clinically indicated. 1 Plasma concentrations of glecaprevir and pibrentasvir may be reduced when glecaprevir/pibrentasvir is coadministered with carbamazepine, efavirenz, and St. John's wort, resulting in reduced therapeutic effect. The concomitant use of these agents with glecaprevir/pibrentasvir is not recommended. 1 Glecaprevir/pibrentasvir use is not recommended in patients with moderate hepatic impairment (Child-Pugh B). 1 There are no adequate and well-controlled studies of glecaprevir/pibrentasvir in pregnant women. Glecaprevir/pibrentasvir should be used during pregnancy only if clearly needed. 1 Caution should be used when administering glecaprevir/ pibrentasvir to a breastfeeding woman. No studies have been conducted to assess the presence of glecaprevir or pibrentasvir in human milk or its effects on breastfeeding infants or human milk production. 
Adverse Reactions
The most frequently observed adverse reactions during glecaprevir/pibrentasvir clinical trials were headache (13%), fatigue (11%), and nausea (8%). Table 3 includes the adverse reactions observed in treatment-naive patients without cirrhosis treated with glecaprevir/pibrentasvir for 8 or 12 weeks or daclatasvir plus sofosbuvir for 12 weeks in a comparative trial. 
Drug Interactions
Glecaprevir and pibrentasvir are inhibitors of P-gp, breast cancer resistance protein (BCRP), and organic anion transporting polypeptide (OATP) 1B1/3. Coadministration with glecaprevir/pibrentasvir may increase plasma concentrations of drugs that are substrates of P-gp, BCRP, or OATP1B1 or OATP1B3. Glecaprevir and pibrentasvir are also weak inhibitors of CYP3A and 1A2, and of uridine glucuronosyltransferase (UGT) 1A1. 1 Glecaprevir and pibrentasvir are substrates of P-gp and/or BCRP. Glecaprevir is a substrate of OATP1B1/3. Coadministration of glecaprevir/pibrentasvir with drugs that inhibit P-gp, BCRP, or OATP1B1/3 may increase plasma concentrations of glecaprevir and/or pibrentasvir. Coadministration with drugs that induce P-gp or CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations. Carbamazepine, efavirenz, and St. John's wort, all potent P-gp/CYP3A inducers, may significantly decrease glecaprevir and pibrentasvir plasma concentrations, leading to reduced therapeutic effect. Therefore, concomitant use of these agents with glecaprevir/pibrentasvir is not recommended. Table 4 summarizes clinically important drug interactions with glecaprevir/pibrentasvir. 1 Interactions are not anticipated when glecaprevir/pibrentasvir is coadministered with substrates of CYP3A, 1A2, 2C9, 2C19, or 2D6, or of UGT1A1 or UGT1A4. Clinically significant interactions have not been observed and no dose adjustment is required when glecaprevir/pibrentasvir is coadministered with the following drugs: abacavir, Note. ↑ = increased; ↓ = decreased; ↔ = no effect. ALT = alanine aminotransferase; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A. 
Recommended Monitoring
Before initiating treatment with glecaprevir/pibrentasvir, patients should be tested for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).
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Dosing
The recommended dosage is 3 tablets taken once daily with food (total daily dose, glecaprevir 300 mg/pibrentasvir 120 mg). Treatment duration varies from 8 weeks to 16 weeks, depending on previous treatment and the presence of cirrhosis (see Table 5 ). 1 No dosing adjustments are necessary for patients with mild, moderate, or severe renal impairment, including those on dialysis. 1 No dosing adjustments are necessary for patients with mild hepatic impairment (Child-Pugh A). Use in patients with moderate hepatic impairment (Child-Pugh B) is not recommended, and use is contraindicated in patients with severe hepatic impairment (Child-Pugh C). 
Drug Safety/Risk Evaluation and Mitigation Strategy (REMS)
No REMS is required for glecaprevir/pibrentasvir.
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Conclusion
Glecaprevir/pibrentasvir is approved for treatment of patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (ChildPugh A), and for the treatment of patients with HCV genotype 1 infection who have previously been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. In clinical trials of HCV patients, glecaprevir/pibrentasvir produced high SVR12 rates in treatment-naive and treatment-experienced patients with renal impairment, prior renal and liver transplant, or coinfection with HIV-1. Glecaprevir/pibrentasvir has demonstrated good tolerability but is associated with drug interactions that may limit its use in certain patients.
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